Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): Overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial. - Sartor,A.O.; Petrylak,D.P.; Witjes,J.A. (J Clin Oncol, 2008)